Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 7/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL15743043 | 0.91 | ALDH1A1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL827328 | 0.85 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6796507 | 0.84 | ALDH1A1 (0.49) | CA12CA1CA2CA7CA9 | |
| 1,4-Diallyloxybenzene SCHEMBL302448 | 0.82 | CA12 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL26361576 | 0.82 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11338395 | 0.81 | CHRNB2 (0.47) | MAOBAOC3ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6232531 | 0.80 | SMN1; SMN2 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL827011 | 0.80 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15880460 | 0.80 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11322795 | 0.80 | CA12 (0.49) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024239000-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | ENVEDA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-116621723-B | Method for oxidizing non-activated end group olefin into secondary alcohol | 江苏科技大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-116621723-A | Method for oxidizing non-activated end group olefin into secondary alcohol | 江苏科技大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-113735669-B | Method for constructing alpha-acyllactam quaternary carbon chiral center compound by nickel-catalyzed asymmetric allyl alkylation and compound | 四川大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3428162-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3428162-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | Merial Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10155725-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-1578715-B1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORP (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | CANTIN LOUIS-DAVID | 2010-08-12 | — | — | US | disclosed |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | CANTIN LOUIS-DAVID | 2010-08-12 | — | — | US | disclosed |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | CANTIN LOUIS-DAVID | 2010-08-12 | — | — | US | disclosed |
| US-7714004-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714004-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714004-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20060084680-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1578715-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058174-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084680-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | CA12 1303/4885CA1 1294/4885CA2 1115/4885 |
| US-10155725-B2 | Anthelmintic compounds and compositions and method of using thereof | CYP3A5, ABCC5, CXXC5 | CA12 2469/4885CA1 1679/4885CA2 732/4885 |
| US-20100204472-A1 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | INSR, ACACA, IAPP | CA12 1303/4885CA1 1294/4885CA2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.